Mean Platelet Volume as an Independent Predictive Marker for Pathologic Complete Response after Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer

  • Mutlu, Hasan (Department of Medical Oncology, Akdeniz University School of Medicine) ;
  • Eryilmaz, Melek Karakurt (Department of Medical Oncology, Akdeniz University School of Medicine) ;
  • Musri, Fatma Yalccn (Department of Medical Oncology, Akdeniz University School of Medicine) ;
  • Gunduz, Seyda (Department of Medical Oncology, Antalya Research and Training Hospital) ;
  • Salim, Derya Kivrak (Department of Medical Oncology, Akdeniz University School of Medicine) ;
  • Coskun, Hasan Senol (Department of Medical Oncology, Akdeniz University School of Medicine)
  • Published : 2016.06.01


Background: The impact of mean platelet volume (MPV) on prognosis, diagnosis and response to therapy in cancer patients has been widely investigated. In the present study, we evaluated whether MPV at diagnosis has predictive value for pathologic complete response (pCR) after neoadjuvant chemotherapy in patients with locally advanced breast cancer (LABC). Materials and Methods: A total of 109 patients with LABC from Akdeniz University and Antalya Research and Training Hospital were evaluated retrospectively. Results: ROC curve analysis suggested that the optimum MPV cut-off point for LABC patients with pCR (+) was 8.15 (AUC:0.378, 95%CI [0.256-0.499], p=0.077). The patients with MPV <8.15 had higher pCR rates (29.2% vs. 13.1%, p=0.038). After binary logistic regression analysis, MPV and estrogen receptor absence were independent predictors for pCR. Conclusions: MPV has an independent predictive value for pCR after neoadjuvant chemotherapy in patients with LABC.


  1. Aliustaoglu M, Bilici A, Seker M, et al (2010). The association of pre-treatment peripheral blood markers with survival in patients with pancreatic cancer. Hepatogastroenterol, 5, 640-45.
  2. Bear HD, Anderson S, Smith RE, et al (2006). Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol, 24, 2019-27.
  3. Berruti A, Amoroso V, Gallo F, et al (2014). Pathologic complete response as a potential surrogate for the clinical outcome in patients withbreast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies. J Clin Oncol, 32, 3883-91.
  4. Buzdar AU, Ibrahim NK, Francis D, et al (2005). Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol, 23, 3676-85.
  5. Canan A, Halicioglu SS, Gurel S (2012). Mean platelet volume and D-dimer in patients with suspected deep venous thrombosis. J Thromb Thrombolysis, 34, 283-7.
  6. Colleoni M, Viale G, Zahrieh D, et al (2004). Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res, 10, 6622-8.
  7. Cristofanilli M, Gonzalez-Angulo A, Sneige N, et al (2005). Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol, 23, 41-8.
  8. Davi G, Patrono C (2007). Platelet activation and atherothrombosis. NEngl Jmed, 357, 2482-94.
  9. Dirican A, Kucukzeybek Y, Erten C, et al (2013). Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha. Asian Pac J Cancer Prev, 14, 2101-5.
  10. Eryilmaz MK, Mutlu H, Salim DK, et al (2014). The neutrophil to lymphocyte ratio has a high negative predictive value for pathologic complete response in locally advanced breast cancer patients receiving neoadjuvant chemotherapy. Asian Pac J Cancer Prev, 15, 7737-40.
  11. Ferlay J, Soerjomataram I, Dikshit R, et al (2012). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 136, 359-86.
  12. Gralow JR, Burstein HJ, Wood W , et al (2008). Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol, 26, 814-19.
  13. Greisenegger S, Endler G, Hsieh K, et al (2004). Is elevated mean platelet volume associated with a worse outcome in patients with acute ischemic cerebrovascular events? Stroke, 35, 1688-91.
  14. Guthrie GJ, Charles KA, Roxburgh CS, et al (2013). The systemic inflammation-based neutrophil-lymphocyte ratio: 45 experience in patients with cancer. Crit Rev Oncol Hematol, 88, 218-30.
  15. Han JS, Park TS, Cho SY, et al (2013). Increased mean platelet volume and mean platelet volume/platelet count ratio in Korean patients with deep vein thrombosis. Platelets, 24, 590-3.
  16. Inagaki N, Kibata K, Tamaki T, et al (2014). Prognostic impact of the mean platelet volume/platelet count ratio in terms of survival in advanced non-small cell lung cancer. Lung Cancer, 83, 97-101.
  17. Kim KI, Lee KH, Kim TR, et al (2014). Ki-67 as a predictor of response to neoadjuvant chemotherapy in breast cancer patients. J Breast Cancer, 17, 40-6.
  18. Kobayashi T, Teruya M, Kishiki T, et al (2008). Inflammation-based prognostic score, prior to neoadjuvant chemoradiotherapy, predicts postoperative outcome in patients with esophageal squamous cell carcinoma. Surgery, 144, 729-35.
  19. Koh YW, Lee HJ, Ahn JH, et al (2014). Prognostic significance of the ratio of absolute neutrophil to lymphocyte counts for breast cancerpatients with ER/PR-positivity and HER2- negativity in neoadjuvant setting. Tumour Biol, 35, 9823-30.
  20. Kong X, Moran MS, Zhang N, et al (2011). Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer, 47, 2084-90.
  21. Krauthamer M, Rouvinov K, Ariad S, et al (2013). A study of inflammation-based predictors of tumor response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Oncol, 85, 27-32.
  22. Madan SA, John F, Pitchumoni CS (2016). Nonalcoholic Fatty Liver Disease and Mean Platelet Volume: A Systemic Review and Meta-analysis. J Clin Gastroenterol, 50, 69-74.
  23. Noble F, Hopkins J, Curtis N, et al (2013). The role of systemic inflammatory and nutritional blood-borne markers in predicting response to neoadjuvant chemotherapy and survival in oesophagogastric cancer. Med Oncol, 30, 596.
  24. Pistelli M, De Lisa M, Ballatore Z, et al (2015). Pre treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients. BMC Cancer, 15, 195.
  25. Sansanayudh N, Anothaisintawee T, Muntham D, et al (2014). Mean platelet volume and coronary artery disease: a systematic review and meta-analysis. Int J Cardiol, 175, 433-40.
  26. Tuncel T, Ozgun A, Emirzeoglu L, et al (2014). Mean platelet volume as a prognostic marker in metastatic colorectal cancer patients treated with bevacizumab-combined chemotherapy. Asian Pac J Cancer Prev, 15, 6421-23.
  27. von Minckwitz G (2013). Neoadjuvant therapy: what are the lessons so far? Hematol Oncol Clin North Am, 27, 767-84.
  28. Yao M, Liu Y, Jin H, et al (2014). Prognostic value of preoperative inflammatory markers in Chinese patients with breast cancer. Onco Targets Ther, 7, 1743-52.